A Plethora of GLP-1 Agonists: Decisions About What to Use and When (Q38987110)

8 September 2017

1 reference

title

A Plethora of GLP-1 Agonists: Decisions About What to Use and When (English)

1 reference

8 September 2017

Susan L Samson

1

1 reference

PubMed ID

27766579

8 September 2017

Alan J Garber

series ordinal

2

1 reference

8 September 2017

1 December 2016

1 reference

8 September 2017

Current diabetes report

1 reference

8 September 2017

16

1 reference

8 September 2017

12

1 reference

8 September 2017

120

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-016-0823-6

8 September 2017

0 references

cites work

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

New ways in which GLP-1 can regulate glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Liraglutide: a once-daily human glucagon-like peptide-1 analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Hyperglycemia and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

The effect of glucagon-like peptide 1 on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Cardiovascular actions of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Cardiovascular effects of incretin therapy in diabetes care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Incretins and preservation of endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-016-0823-6

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

12 December 2020

Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

12 December 2020

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

12 December 2020

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Candidate hormones of the gut. 3. Gastric inhibitory polypeptide (GIP)

1 reference

12 December 2020

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59.

1 reference

12 December 2020

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

1 reference

12 December 2020

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

1 reference

12 December 2020

Impact of lack of suppression of glucagon on glucose tolerance in humans

1 reference

12 December 2020

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Discussion on the Therapeutic Value of Hormones

1 reference

12 December 2020

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis

1 reference

12 December 2020

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

1 reference

12 December 2020

The glucagon superfamily: precursor structure and gene organization

1 reference

12 December 2020

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Tri

1 reference

12 December 2020

Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59

1 reference

12 December 2020

Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes

1 reference

12 December 2020

Intestinal Factors in the Control of Insulin Secretion

1 reference

12 December 2020

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

1 reference

12 December 2020

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

1 reference

12 December 2020

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

1 reference

12 December 2020

Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

10.1007/S11892-016-0823-6

Identifiers

DOI

1 reference

PubMed ID

27766579

Dimensions Publication ID

8 September 2017

0 references

1 reference

PubMed ID

27766579